Response of Daclatasvir and Sofosbuvir in Treatment-Naïve, HCV Genotype 3, Non-Cirrhotic Pakistani Population: 1 Year Follow-Up Experience

using daclatasvir and sofosbuvir in treatment-naive, non-cirrhotic HCV genotype 3 Pakistani population. Methodology: From January 2017 to February 2019, patients who met the inclusion criteria were included this open-label, non-randomized, uncontrolled observational trial at HBS General Hospital Islamabad. A 12-week course of oral therapy was administered each participant. Each patient got 400mg 60mg daclatasvir. Treatment outcomes sustained virological response (SVR12 SVR24), rapid (RVR), end-of-treatment (ETR) as primary secondary respectively. Results: There 105 participants study, which 72.3% male 27.6% female. RVR for 92% (p=0.002), while it 89.65% female (p=0.004). 96.05% 93.1% achieved ETR (p=0.002). Both 93.4% had SVR12 (p=0.001). single experienced relapse after achieving (p=060). SVR24 rates 92.1% (p=0.003) 93.1%, The combination well-tolerated, with side effect being fatigue (36% males, 44% females). Conclusion: demonstrated both safety efficacy treating treatment-naïve, individuals Pakistan. study underscores potential direct-acting antiviral agents addressing challenge infections.